Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPMT | P51580 | 2/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | HCAR1 | Q9BXC0 | 2/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.38 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | RAB9A | P51151 | 4/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL111207 | 0.85 | TPMT (0.59) | TPMTCA5AKDRHCAR1LMNA | |
| Hydrochloric Acid SCHEMBL28868737 | 0.83 | TPMT (0.56) | TPMTCA5AKDRHCAR1LMNA | |
| SCHEMBL2624954 | 0.83 | TPMT (0.55) | TPMTCA5ACYP2A6HCAR1LMNA | |
| SCHEMBL95695 | 0.83 | TPMT (0.62) | TPMTCA5ACYP2A6HCAR1LMNA | |
| SCHEMBL2172128 | 0.82 | TPMT (0.44) | TPMTKDRHCAR1CES2CES1 | |
| SCHEMBL668260 | 0.82 | TPMT (0.44) | TPMTKDRHCAR1CES2CES1 | |
| SCHEMBL29912669 | 0.82 | TPMT (0.44) | TPMTKDRHCAR1CES2CES1 | |
| SCHEMBL2172133 | 0.82 | TPMT (0.70) | TPMTKDRHCAR1SMN1; SMN2CNR2 | |
| SCHEMBL22383502 | 0.80 | PARP1 (0.50) | TPMTKDRHCAR1CES2CES1 | |
| SCHEMBL14110107 | 0.80 | TPMT (0.43) | TPMTCA5AKDRHCAR1CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9174969-B2 | Indoline scaffold SHP-2 inhibitors and cancer treatment method | UNIVERSITY OF SOUTH FLORIDA (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150239889-A1 | PYRAZOLOPYRIMIDINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-08-27 | — | — | US | disclosed |
| US-20110190315-A1 | INDOLINE SCAFFOLD SHP-2 INHIBITORS AND CANCER TREATMENT METHOD | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239889-A1 | PYRAZOLOPYRIMIDINE COMPOUND | HIF1AN, EGLN2, EGLN3 | TPMT 1953/4885CA5A 186/4885KDR 164/4885 |
| US-20110190315-A1 | INDOLINE SCAFFOLD SHP-2 INHIBITORS AND CANCER TREATMENT METHOD | PTPN7, PTPN3, PTPN5 | TPMT 2881/4885CA5A 1800/4885KDR 740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.